@prefix rdfs:    <http://www.w3.org/2000/01/rdf-schema#> .
@prefix foaf:    <http://xmlns.com/foaf/0.1/> .
@prefix owl:     <http://www.w3.org/2002/07/owl#> .
@prefix vocabProperty:  <http://www4.wiwiss.fu-berlin.de/drugbank/vocab/resource/property/> .
@prefix drugbank:  <http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/> .
@prefix dbpedia:  <http://dbpedia.org/ontology/> .
@prefix map:     <file:/C:/apps/drugbank/drugbank.n3#> .
@prefix rdf:     <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix trc:     <http://www.trialresultscenter.org/property/> .
<http://www.trialresultscenter.org/study11238-WHS vitamin E.htm>    <trc:trial_id>11238</trc:trial_id>spc+<trc:name>WHS vitamin E, 2005</trc:name>spc+<trc:registre>NCT00000479</trc:registre>    trc:studiedTreatment "vitamin E 600 IU every other day (á-tocopherol)";    <trc:studiedTreatmentDetail><![CDATA[]]></trc:studiedTreatmentDetail>    <trc:controlTreatment><![CDATA[placebo]]></trc:controlTreatment>    <trc:controlTreatmentDetail><![CDATA[]]></trc:controlTreatmentDetail>    <trc:concomittantTreatment><![CDATA[]]></trc:concomittantTreatment>    <trc:patients><![CDATA[apparently healthy US women aged at least 45 years]]></trc:patients>    <trc:exclusionCriteria><![CDATA[]]></trc:exclusionCriteria>    <trc:inclusionCriteria><![CDATA[age 45 years or older; no previous history of coronary heart disease, cerebrovascular disease, cancer (except nonmelanoma skin cancer), or other major chronic illnesses; no history of adverse effects from aspirin; no use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) more than once a week, or willingness to forgo their use; no use of anticoagulants or corticosteroids; and no use of individual supplements of vitamin A, E, or beta carotene more than once a week]]></trc:inclusionCriteria>    <trc:exclusionReason><![CDATA[]]></trc:exclusionReason>    <trc:N1>19937</trc:N1>    <trc:N0>19939</trc:N0>    <trc:design>Factorial plan</trc:design>    <trc:inclusionPeriod>sept 1992 - may 1995</trc:inclusionPeriod>    <trc:blindness>double-blind</trc:blindness>    <trc:FUduration>10.1 y</trc:FUduration>    <trc:lostFU>2.8% (morbidity)</trc:lostFU>    <trc:comment></trc:comment>    <trc:primaryEndpoint>major cardiovascular event</trc:primaryEndpoint><trc:demonstratedBenefit>yes</trc:demonstratedBenefit>    <trc:jadad>5</trc:jadad>    <trc:centre></trc:centre>    <trc:area>US</trc:area>    <trc:remarkTreatment><![CDATA[factorial design vitamin E or placebo and aspirin or placebo]]></trc:remarkTreatment>    <trc:remarkPatient><![CDATA[]]></trc:remarkPatient>    <trc:remarkMethod><![CDATA[two primary endpoint specified without method for dealing with multiplicity]]></trc:remarkMethod>    <trc:hypothesis>Superiority</trc:hypothesis>    <trc:register>NCT00000479</trc:register>    <trc:studyType>2</trc:studyType>    <trc:question>cardiovascular prevention antioxydants all type of patients</trc:question>    <trc:question>cardiovascular prevention antioxydants primary prevention</trc:question>    <trc:pathology>cardiovascular prevention</trc:pathology>    <trc:mecanism>antioxydants</trc:mecanism>    <trc:patient>All type of patient</trc:patient>    <trc:patient>primary prevention</trc:patient>